Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0001140361-17-033210

Options or other derivatives

  • Chief Financial Officer and VP acquired 58,500 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

York Charles N II · Chief Financial Officer and VP

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2017-08-22 Grant or award : show line 1 in the form Employee Stock Option (right to buy) +58,500 58,500 D
Loading xslF345X03/doc1.xml…